Efficacy and safety of capecitabine in treatment of colorectal cancer
10.3969/j.issn.1006-5725.2017.19.035
- VernacularTitle:卡培他滨单药治疗老年大肠癌的疗效和安全性
- Author:
Zhuangwei FANG
1
;
Bo YUAN
;
Ping HUANG
;
Weiping ZHOU
;
Guohao CAI
;
Yong FU
;
Qinghua WANG
;
Youqun HUANG
;
Kejian ZOU
;
Renfeng MULIN
;
LI YE
Author Information
1. 海南省人民医院胃肠外二科
- Keywords:
colorectal cancer;
capecitabine;
efficacy;
safety
- From:
The Journal of Practical Medicine
2017;33(19):3287-3290
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and safety of capecitabine in the treatment of colorectal cancer. Methods Totally 160 elderly patients with stageⅣcolorectal cancer were enrolled in this study. After first-line combined chemotherapy,80 patients were treated with capecitabine monotherapy(maintenance group)and another 80 cases were not(control group). The survival rate was analyzed by Kaplan-Meier curve and the efficiency and incidence of adverse events were compared. Results (1) The Kaplan-Meier curve suggested that the difference between two groups was statistically significant(P<0.05).(2)The response rate of maintenance group was significantly higher than that of control group (P < 0.05). (3)The incidence of adverse events during capecitabine monotherapy was lower than that during combined chemotherapy(P < 0.05).(4)The incidence of adverse reactions during capecitabine monotherapy was similar to that of control group(P > 0.05). Conclusion Capecitabine monotherapy in patients with stage Ⅳ colorectal cancer after combined chemotherapy has a longer median PFS than those without maintenance but similar adverse reactions ,which was worthy of clinical promotion.
